Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
12 participants
INTERVENTIONAL
2025-03-01
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
NCT03408561
Breast Cancer Trials Education Program
NCT02808598
The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors
NCT03980093
Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials
NCT06484595
INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy
NCT06246084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The TEDD tool is designed to give medical professionals feedback on how diverse their patient enrollments are clinical trials. By using this tool, medical professionals can see if they are enrolling a diverse group of patients and make changes if needed.
The study will involve a small group of medical professionals who treat leukemia patients. They will use the TEDD tool and provide feedback on its usability and effectiveness. Study procedures include completion of surveys and usage of the TEDD intervention dashboard.
It is expected that about 12 medical professionals will take part in this research study. Participation in this research study is expected to last about 14 months.
The National Cancer Institute is providing funding for this research study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TEDD Intervention
12 medical professional participants will complete the following:
* Baseline survey.
* Usage and access of the TEDD intervention over a 12-month period.
* Follow up surveys at the end of each quarter.
Trial Enrollment Diversity Dashboard Behavioral
A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trial Enrollment Diversity Dashboard Behavioral
A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
-≥10% clinical effort (or one ½ day of clinic per week for those working \<1 FTE)
* Treats adult patients with leukemia or related diseases at the study sites
* Ability to understand and willingness to provide informed consent
* Age 18 or older
* Age ≥18 years old
* Diagnosis of leukemia, lymphoma, myeloma, or related diseases
* Seen by a physician for this diagnosis at one of the study sites
Exclusion Criteria
-Participants without the diagnoses of interest listed above, participants not seen at the study sites.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
American Society of Clinical Oncology
OTHER
Dana-Farber Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrew Hantel, MD
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Hantel, MD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-544
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.